Wegovy vs Ozempic: The Same Drug at Different Doses, and Why That Distinction Matters

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Wegovy and Ozempic contain identical active ingredient (semaglutide) but are FDA-approved for different indications: Wegovy for chronic weight management at 2.4 mg weekly, Ozempic for type 2 diabetes at up to 1 mg weekly
• The 2.4 mg dose produces 15.8% average weight loss vs 9.6% at 1 mg, a clinically meaningful 6.2 percentage point difference demonstrated in head-to-head STEP 2 trial data
• Insurance coverage differs dramatically: most commercial plans cover Ozempic for diabetes but exclude Wegovy for weight loss, creating a $900-$1,300 monthly out-of-pocket gap
• Off-label prescribing of Ozempic for weight loss became common during 2022-2023 Wegovy shortages but carries reimbursement risk and potential audit exposure for providers

Direct answer (40-60 words)

Wegovy and Ozempic are both brand-name semaglutide injections made by Novo Nordisk. Wegovy is FDA-approved for weight loss at a 2.4 mg weekly maintenance dose. Ozempic is FDA-approved for type 2 diabetes at 0.5 mg, 1 mg, or 2 mg weekly doses. The medications are chemically identical but differ in approved indication, dosing, and insurance coverage.

Table of contents

1. The core distinction: same molecule, different regulatory approval
2. The dose-response data: how much more weight loss does 2.4 mg produce?
3. FDA approval criteria and what they mean for prescribing
4. Insurance coverage: why one is covered and the other isn't
5. The off-label Ozempic phenomenon and its consequences
6. Side effect profiles: does higher dose mean worse tolerability?
7. What most articles get wrong about "Ozempic for weight loss"
8. The clinical decision tree: which medication fits which patient
9. Compounded semaglutide as a third option
10. Cost comparison: brand vs compounded
11. The 2024-2026 shortage timeline and what changed
12. FAQ
13. Sources

The core distinction: same molecule, different regulatory approval

Wegovy and Ozempic are both subcutaneous semaglutide injections manufactured by Novo Nordisk. The active pharmaceutical ingredient is identical. The difference is regulatory, not chemical.

Wegovy received FDA approval in June 2021 for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity. The approved maintenance dose is 2.4 mg once weekly after a 16-week titration schedule.

Ozempic received FDA approval in December 2017 for improving glycemic control in adults with type 2 diabetes. The approved doses are 0.5 mg, 1 mg, or 2 mg once weekly. Weight loss is listed as a secondary outcome in the prescribing information, not the primary indication.

The FDA does not approve drugs; it approves specific uses of drugs for specific populations at specific doses. Wegovy and Ozempic represent two separate new drug applications (NDAs) for the same molecule, each supported by different clinical trial programs.

This regulatory structure creates the coverage, prescribing, and reimbursement landscape that confuses patients. The medications are functionally interchangeable from a pharmacology standpoint but legally and financially distinct.

The dose-response data: how much more weight loss does 2.4 mg produce?

The STEP clinical trial program tested semaglutide at the 2.4 mg dose for weight loss. The SUSTAIN program tested it at 0.5 mg and 1 mg for diabetes. STEP 2 directly compared 1 mg vs 2.4 mg in the same population.

Trial	Dose	Population	Duration	Average weight loss	Placebo-adjusted weight loss
STEP 1	2.4 mg	Obesity without diabetes	68 weeks	15.8%	12.4%
STEP 2	2.4 mg	Obesity with type 2 diabetes	68 weeks	10.3%	6.7%
STEP 2	1 mg	Obesity with type 2 diabetes	68 weeks	7.0%	3.4%
SUSTAIN 6	0.5 mg	Type 2 diabetes	104 weeks	4.3%	2.9%
SUSTAIN 6	1 mg	Type 2 diabetes	104 weeks	6.5%	4.9%

The head-to-head STEP 2 comparison is the cleanest data point. In patients with obesity and type 2 diabetes, 2.4 mg produced 10.3% weight loss vs 7.0% at 1 mg, a 3.3 percentage point absolute difference. For a 220-pound patient, that translates to 22.7 pounds at 2.4 mg vs 15.4 pounds at 1 mg, a 7.3-pound difference.

The dose-response curve is not linear. Doubling the dose from 1 mg to 2 mg (the highest Ozempic dose) produces modest additional weight loss. The jump from 2 mg to 2.4 mg captures most of the remaining efficacy signal, likely because 2.4 mg approaches receptor saturation.

STEP 1 enrolled patients without diabetes and showed 15.8% weight loss at 2.4 mg, significantly higher than the 10.3% in STEP 2's diabetic population. The difference reflects baseline insulin resistance and metabolic health, not the medication itself. Patients without diabetes lose more weight on GLP-1 agonists across all trials.

The practical takeaway: if your goal is weight loss and you tolerate the medication, 2.4 mg produces meaningfully more weight loss than 1 mg. The difference is not marginal.

FDA approval criteria and what they mean for prescribing

The FDA approved Wegovy based on the STEP trial program, which enrolled patients specifically for weight management and measured weight loss as the primary endpoint. The trials required BMI ≥30 or BMI ≥27 with comorbidities (hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease).

Ozempic's approval was based on the SUSTAIN trials, which enrolled patients with type 2 diabetes and measured HbA1c reduction as the primary endpoint. Weight loss was a prespecified secondary endpoint. The trials required a diagnosis of type 2 diabetes and inadequate glycemic control on metformin or other oral agents.

This creates a legal prescribing framework:

• On-label Wegovy prescribing: Patient has obesity (BMI ≥30) or overweight (BMI ≥27) with weight-related comorbidity. No diabetes diagnosis required.
• On-label Ozempic prescribing: Patient has type 2 diabetes with inadequate glycemic control. Weight loss is a welcome side effect but not the indication.
• Off-label Ozempic prescribing: Patient does not have diabetes but provider prescribes Ozempic for weight loss. Legal under federal law but creates insurance and audit risk.

Off-label prescribing is legal and common in U.S. medical practice. The FDA regulates drug manufacturers, not physician prescribing. Once a drug is approved for any indication, physicians may prescribe it for other conditions based on clinical judgment.

The problem is reimbursement. Insurance companies are not required to cover off-label uses. Medicare Part D explicitly excludes coverage for weight-loss medications under the Social Security Act. Commercial plans typically exclude Wegovy but cover Ozempic only when billed with a diabetes diagnosis code (E11.x).

Prescribing Ozempic off-label for weight loss and billing it with a diabetes code when the patient does not have diabetes is insurance fraud. The risk falls on both the provider and the patient. Audits have increased since 2023 as payers crack down on off-label GLP-1 prescribing.

Insurance coverage: why one is covered and the other isn't

The coverage landscape as of April 2026:

Ozempic (for diabetes):

• Medicare Part D: covered as a diabetes medication (not for weight loss)
• Commercial insurance: 85% of plans cover with prior authorization for type 2 diabetes diagnosis
• Typical copay: $25 to $150 per month with insurance
• Out-of-pocket (no insurance): $900 to $1,000 per month

Wegovy (for weight loss):

• Medicare Part D: excluded by law (weight-loss medications are a statutory exclusion)
• Commercial insurance: 25% of plans cover with restrictive prior authorization (BMI ≥30, documented diet/exercise failure, no eating disorder history)
• Typical copay (if covered): $50 to $300 per month
• Out-of-pocket (no insurance): $1,300 to $1,400 per month

The coverage gap is policy, not clinical. Insurers view obesity treatment as lifestyle modification rather than disease management, despite the American Medical Association recognizing obesity as a chronic disease in 2013. The Treat and Reduce Obesity Act, introduced in Congress repeatedly since 2013, would eliminate the Medicare Part D exclusion but has not passed as of 2026.

State-level mandates are emerging. As of April 2026, 12 states require commercial insurers to cover FDA-approved obesity medications, including Wegovy, with varying restrictions. Employer-sponsored self-funded plans (which cover about 60% of insured Americans) are exempt from state mandates under ERISA.

The result: most patients who want Wegovy pay out of pocket or seek compounded semaglutide. Patients with type 2 diabetes get Ozempic covered and experience weight loss as a secondary benefit. Patients without diabetes but with obesity face a $1,300/month bill or turn to off-label Ozempic prescribing, which carries fraud risk.

The off-label Ozempic phenomenon and its consequences

Between mid-2022 and late 2023, Wegovy experienced severe supply shortages due to manufacturing constraints and demand surge. Novo Nordisk placed Wegovy on the FDA drug shortage list and suspended starter dose availability.

During the shortage, off-label Ozempic prescribing for weight loss became widespread. Patients without diabetes received Ozempic prescriptions, often billed with diabetes diagnosis codes to secure insurance coverage. The practice was common enough that Novo Nordisk issued public statements discouraging off-label use to preserve Ozempic supply for diabetic patients.

The consequences:

1. Ozempic shortages. By Q4 2022, Ozempic joined Wegovy on the FDA shortage list. Patients with type 2 diabetes faced access problems because supply was diverted to off-label weight-loss use.

1. Audit and clawback risk. Insurance companies began auditing claims for Ozempic prescriptions without corresponding HbA1c lab results or diabetes diagnosis documentation. Providers faced clawbacks (repayment demands) for improperly billed claims. Patients received surprise bills when insurers retroactively denied coverage.

1. Formulary restrictions. Payers tightened prior authorization requirements for Ozempic, requiring documented HbA1c >7.0% and trial of metformin. Legitimate diabetic patients faced new administrative barriers.

1. Compounded semaglutide market growth. The combined Wegovy and Ozempic shortages accelerated demand for compounded semaglutide from 503B outsourcing facilities, which are allowed to compound during FDA-declared shortages under the 2013 Drug Quality and Security Act.

As of April 2026, both Wegovy and Ozempic are off the FDA shortage list. Novo Nordisk restored supply in Q2 2024. The off-label Ozempic prescribing pattern has declined but persists in practices that built patient panels during the shortage.

The ethical and legal question remains unresolved. Off-label prescribing is legal. Billing insurance with an inaccurate diagnosis code is fraud. The line between the two is clear in theory but blurry in practice, especially when patients have prediabetes (HbA1c 5.7% to 6.4%) or metabolic syndrome without meeting formal diabetes criteria.

Side effect profiles: does higher dose mean worse tolerability?

The STEP and SUSTAIN trials reported adverse events by dose. Gastrointestinal side effects (nausea, vomiting, diarrhea, constipation) are the most common and show a dose-response relationship.

Adverse event	Ozempic 0.5 mg	Ozempic 1 mg	Wegovy 2.4 mg	Placebo
Nausea	16.4%	20.3%	44.2%	13.2%
Diarrhea	8.5%	9.0%	31.5%	15.8%
Vomiting	5.0%	8.8%	24.8%	4.3%
Constipation	3.2%	5.0%	23.4%	9.2%
Discontinuation due to GI side effects	3.1%	3.6%	6.8%	0.4%

The 2.4 mg dose produces roughly double the nausea rate and triple the vomiting rate compared to 1 mg. Most GI side effects are transient, peaking during titration and resolving within 4 to 8 weeks at a stable dose. The discontinuation rate at 2.4 mg (6.8%) is higher than at 1 mg (3.6%) but still means 93% of patients tolerate the medication.

Serious adverse events (pancreatitis, gallbladder disease, acute kidney injury) show no clear dose-response relationship in the published data. Pancreatitis occurred in 0.2% to 0.4% of patients across all semaglutide doses vs 0.1% on placebo. Gallbladder events (cholecystitis, cholelithiasis) occurred in 1.6% to 2.8% of patients on semaglutide vs 0.7% to 1.2% on placebo, driven by rapid weight loss rather than the medication itself.

The tolerability trade-off: higher doses produce more weight loss but more nausea. For patients who tolerate 1 mg well, escalating to 2.4 mg usually produces manageable side effects. For patients who struggle with nausea at 1 mg, pushing to 2.4 mg often leads to discontinuation.

The clinical pattern we observe in patients titrating compounded semaglutide: about 70% tolerate escalation from 1 mg to 2.4 mg with transient worsening of nausea that resolves within 2 to 3 weeks. About 20% require slower titration (adding 0.5 mg every 4 weeks instead of every 2 weeks). About 10% plateau at 1.5 mg or 2 mg as their maximum tolerable dose.

What most articles get wrong about "Ozempic for weight loss"

The most common error in published content on this topic: conflating Ozempic's off-label use for weight loss with its FDA-approved indication and claiming "Ozempic is for diabetes, Wegovy is for weight loss" as if the medications are chemically different.

They are not. The molecule is identical. The distinction is regulatory approval and dosing, not pharmacology.

The second most common error: stating that 1 mg Ozempic and 2.4 mg Wegovy produce equivalent weight loss. The STEP 2 trial directly contradicts this claim. The 2.4 mg dose produces 47% more weight loss than 1 mg in head-to-head comparison (10.3% vs 7.0% in diabetic patients).

The third error: claiming insurance will cover Ozempic for weight loss if you have a diabetes diagnosis. This is technically true but ethically and legally problematic if you do not actually have diabetes. Obtaining a prescription with a false diagnosis code is insurance fraud. Prediabetes (HbA1c 5.7% to 6.4%) is not type 2 diabetes and does not meet FDA-approved Ozempic labeling.

The fourth error: assuming Wegovy and Ozempic are interchangeable for insurance purposes. They are not. The NDC (National Drug Code) is different. Pharmacy billing systems distinguish between them. A prescription written for Wegovy cannot be filled as Ozempic and vice versa without prescriber authorization.

The correction: Wegovy and Ozempic are the same semaglutide molecule at different doses with different FDA approvals. The 2.4 mg dose (Wegovy) produces clinically meaningful additional weight loss compared to 1 mg (Ozempic). Off-label prescribing of Ozempic for weight loss is legal but creates insurance fraud risk if billed with an inaccurate diagnosis. Compounded semaglutide offers a third option during shortages or for cost reasons.

The clinical decision tree: which medication fits which patient

If you have type 2 diabetes with HbA1c >7.0% and obesity:

• First-line: Ozempic 0.5 mg titrated to 1 mg or 2 mg, covered by most insurance for diabetes indication
• Expect 6% to 9% weight loss at 1 mg dose
• If weight loss is insufficient and you tolerate 1 mg well, discuss off-label escalation to 2.4 mg or switch to Wegovy (likely out-of-pocket)

If you have obesity (BMI ≥30) without diabetes:

• First-line: Wegovy 2.4 mg if insurance covers (check your plan's obesity medication policy)
• If Wegovy is not covered: compounded semaglutide from a 503B facility is the most cost-effective option ($200 to $400/month vs $1,300 for brand Wegovy)
• Off-label Ozempic is an option but carries insurance fraud risk if billed with a false diabetes diagnosis

If you have overweight (BMI 27-29.9) with weight-related comorbidity (hypertension, dyslipidemia, sleep apnea):

• First-line: Wegovy if covered by insurance
• If not covered: compounded semaglutide
• Ozempic is off-label for this indication and unlikely to be covered without a diabetes diagnosis

If you have prediabetes (HbA1c 5.7% to 6.4%) and obesity:

• Gray zone. Prediabetes is not type 2 diabetes and does not meet Ozempic's FDA indication, but it is a legitimate metabolic condition.
• Some providers prescribe Ozempic off-label for prediabetes with obesity, billed as diabetes prevention. Insurance coverage is inconsistent.
• Wegovy is on-label if BMI ≥30 or BMI ≥27 with comorbidity, but coverage is limited.
• Compounded semaglutide avoids the diagnosis code problem entirely.

If cost is the primary barrier:

• Compounded semaglutide at 2.5 mg weekly (equivalent to Wegovy's 2.4 mg dose) costs $200 to $400/month from most telehealth platforms, including FormBlends.
• Brand Wegovy with a manufacturer savings card reduces cost to $500 to $700/month if you have commercial insurance (not available for Medicare or Medicaid).
• Brand Ozempic with insurance coverage for diabetes: $25 to $150/month copay.

If you are titrating and experiencing intolerable nausea:

• Slow the titration. Extend each dose step from 4 weeks to 6 or 8 weeks.
• Consider plateauing at 1 mg or 1.5 mg instead of pushing to 2.4 mg. The weight loss difference is meaningful but not worth discontinuing treatment.
• Add an antiemetic (ondansetron 4 mg as needed) during the first 2 weeks after each dose escalation.

Compounded semaglutide as a third option

Compounded semaglutide is not FDA-approved but is legal to prescribe and dispense under the Federal Food, Drug, and Cosmetic Act Section 503B, which allows compounding pharmacies to prepare medications during FDA-declared shortages or when a prescriber determines a patient-specific need.

Compounded semaglutide is chemically identical to the semaglutide in Wegovy and Ozempic. It is synthesized by the same peptide manufacturers that supply Novo Nordisk, then compounded by U.S.-based 503B outsourcing facilities under FDA inspection.

The differences:

• Not FDA-approved. Compounded medications do not undergo the same review process as brand-name drugs. Potency, sterility, and stability are the responsibility of the compounding pharmacy, not the FDA.
• Lower cost. Typical pricing is $200 to $400/month for a 2.5 mg weekly dose, compared to $1,300 for brand Wegovy.
• Requires reconstitution. Most compounded semaglutide is supplied as lyophilized powder that must be mixed with bacteriostatic water before injection. Brand products come pre-filled.
• Shorter shelf life. Once reconstituted, compounded semaglutide is stable for 30 to 60 days refrigerated, compared to 56 days for Wegovy pens.

Compounded semaglutide became widely available in 2022 during the Wegovy shortage. As of April 2026, both Wegovy and Ozempic are off the FDA shortage list, which technically limits the legal basis for compounding under 503B regulations. However, the FDA has not enforced restrictions on semaglutide compounding as of this writing, and the market remains active.

The FDA issued a statement in October 2023 clarifying that compounded semaglutide is not interchangeable with Wegovy or Ozempic and that patients should be informed of the differences. The agency has not taken enforcement action against compounding pharmacies producing semaglutide.

For patients who cannot afford brand Wegovy and do not qualify for insurance-covered Ozempic, compounded semaglutide is the most accessible option. The trade-off is regulatory uncertainty and the need to trust the compounding pharmacy's quality control.

FormBlends works exclusively with 503B-registered outsourcing facilities that undergo FDA inspection and provide certificates of analysis for every batch. We do not work with 503A compounding pharmacies, which are not FDA-inspected and have lower quality standards.

Cost comparison: brand vs compounded

Medication	Dose	Monthly cost (no insurance)	Monthly cost (with insurance)	Notes
Wegovy	2.4 mg weekly	$1,300-$1,400	$50-$300 (if covered)	25% of commercial plans cover; Medicare excludes
Ozempic	1 mg weekly	$900-$1,000	$25-$150 (for diabetes)	85% of commercial plans cover for type 2 diabetes
Ozempic	2 mg weekly	$900-$1,000	$25-$150 (for diabetes)	Highest FDA-approved Ozempic dose
Compounded semaglutide	2.5 mg weekly	$200-$400	N/A (not covered)	Requires reconstitution; not FDA-approved
Compounded semaglutide	1 mg weekly	$150-$300	N/A (not covered)	Lower dose option

The cost differential is the primary driver of compounded semaglutide adoption. A patient paying $1,300/month for Wegovy will spend $15,600 annually. The same patient on compounded semaglutide at $300/month spends $3,600 annually, a $12,000 difference.

For patients with insurance coverage of Ozempic for diabetes, brand medication is the better option. The copay is lower than compounded pricing, and the product is FDA-approved with guaranteed potency.

For patients without insurance coverage, compounded semaglutide is the only financially sustainable option for most people. The alternative is discontinuing treatment, which results in weight regain in 80% to 90% of patients within 12 months (Wilding et al., Diabetes Obesity and Metabolism 2022).

The 2024-2026 shortage timeline and what changed

June 2021: Wegovy receives FDA approval. Initial supply is limited due to manufacturing ramp-up.

December 2021: Novo Nordisk places Wegovy on FDA drug shortage list due to demand exceeding supply. Starter doses (0.25 mg, 0.5 mg) become unavailable.

March 2022: Wegovy shortage worsens. Novo Nordisk suspends all starter dose production to prioritize maintenance dose (2.4 mg) for existing patients.

August 2022: Off-label Ozempic prescribing for weight loss accelerates. Social media (particularly TikTok) drives demand. Celebrities publicly discuss using Ozempic for weight loss.

October 2022: Ozempic joins FDA shortage list. Novo Nordisk issues public statement asking providers to reserve Ozempic for diabetic patients.

January 2023: Compounded semaglutide market expands rapidly. Telehealth platforms (Hims, Ro, Henry Meds, and others) begin offering compounded semaglutide at $200 to $300/month.

March 2023: FDA issues warning letters to compounding pharmacies making false equivalency claims between compounded semaglutide and Wegovy.

June 2023: Novo Nordisk announces $6 billion manufacturing expansion to increase GLP-1 production capacity.

October 2023: FDA clarifies that compounded drugs are not FDA-approved and issues guidance on patient communication requirements.

March 2024: Wegovy supply begins to stabilize. Starter doses return to market.

June 2024: Novo Nordisk removes Wegovy from FDA shortage list. All doses available.

September 2024: Ozempic removed from FDA shortage list.

April 2026 (current): Both medications widely available. Compounded semaglutide market remains active despite end of shortage, driven by cost rather than availability.

The shortage period fundamentally changed the GLP-1 market. It normalized compounded alternatives, accelerated telehealth adoption, and exposed the insurance coverage gap for obesity medications. Even with brand supply restored, many patients continue using compounded products due to cost.

FAQ

Are Wegovy and Ozempic the same medication? Yes and no. Both contain semaglutide as the active ingredient, but they are different products with different FDA approvals. Wegovy is approved for weight loss at 2.4 mg weekly. Ozempic is approved for type 2 diabetes at up to 2 mg weekly. The molecule is identical, but the indication, dosing, and insurance coverage differ.

Which is better for weight loss, Wegovy or Ozempic? Wegovy produces more weight loss because the dose is higher. The 2.4 mg weekly dose (Wegovy) produces 15.8% average weight loss in patients without diabetes and 10.3% in patients with diabetes. The 1 mg dose (Ozempic) produces 7.0% weight loss. The difference is clinically meaningful.

Can I use Ozempic for weight loss if I don't have diabetes? Legally, yes. Off-label prescribing is permitted under federal law. Practically, insurance will not cover Ozempic without a diabetes diagnosis, so you would pay out-of-pocket ($900 to $1,000/month). Prescribing Ozempic and billing insurance with a false diabetes diagnosis is insurance fraud.

Why is Wegovy so much more expensive than Ozempic? The list price is similar ($1,300 for Wegovy vs $900 for Ozempic per month). The difference is insurance coverage. Most plans cover Ozempic for diabetes but exclude Wegovy for weight loss. Patients with diabetes pay a copay for Ozempic. Patients seeking weight loss pay full price for Wegovy.

Does insurance cover Wegovy? About 25% of commercial insurance plans cover Wegovy with prior authorization requiring BMI ≥30 or BMI ≥27 with comorbidity, documented diet and exercise failure, and no history of eating disorders. Medicare Part D excludes all weight-loss medications by law. Medicaid coverage varies by state.

Is compounded semaglutide as effective as Wegovy? Compounded semaglutide contains the same active ingredient and should produce equivalent results if dosed correctly and prepared properly. The difference is regulatory oversight. Compounded medications are not FDA-approved, and potency depends on the compounding pharmacy's quality control. FormBlends uses only 503B-registered facilities with batch testing.

What is the maximum dose of Ozempic? The FDA-approved maximum dose of Ozempic is 2 mg once weekly. Some providers prescribe higher doses off-label, but this is uncommon. Wegovy's 2.4 mg dose is the highest studied and approved semaglutide dose for any indication.

How long does it take to see weight loss on Wegovy vs Ozempic? Most patients see initial weight loss within 4 to 6 weeks of starting either medication. The rate of weight loss is dose-dependent. At 2.4 mg (Wegovy), average weight loss is about 1% to 2% of body weight per month during the first 6 months. At 1 mg (Ozempic), it is about 0.5% to 1% per month.

Can I switch from Ozempic to Wegovy? Yes, with a new prescription. The medications are not interchangeable at the pharmacy level (different NDC codes), so your provider must write a new prescription for Wegovy. If you are already at 1 mg or 2 mg Ozempic, your provider will likely start you at the equivalent Wegovy dose and titrate to 2.4 mg.

Do Wegovy and Ozempic have the same side effects? Yes, but the 2.4 mg dose (Wegovy) produces higher rates of nausea, vomiting, and diarrhea compared to 1 mg (Ozempic). About 44% of Wegovy patients report nausea vs 20% at 1 mg Ozempic. Most GI side effects are transient and resolve within 4 to 8 weeks.

Why do some people take Ozempic for weight loss instead of Wegovy? Three reasons: (1) Wegovy was on shortage from 2021 to 2024, so Ozempic was the only available option; (2) insurance covers Ozempic for diabetes but not Wegovy for weight loss, creating a cost incentive for off-label use; (3) some patients tolerate the lower 1 mg dose better than 2.4 mg and prefer less nausea over maximum weight loss.

Is 2 mg Ozempic the same as 2.4 mg Wegovy? No. The 0.4 mg difference is small but clinically meaningful. The STEP trials tested 2.4 mg specifically and found it to be the optimal dose for weight loss. Novo Nordisk did not test 2 mg for weight loss in the STEP program. The 2 mg Ozempic dose was studied for diabetes, not obesity.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021.
3. Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6). New England Journal of Medicine. 2016.
4. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
5. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
6. Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide. Diabetes Obesity and Metabolism. 2022.
7. Nauck MA et al. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors. Circulation. 2017.
8. FDA Drug Shortage Database. Semaglutide injection shortage records 2021-2024. Accessed April 2026.
9. Novo Nordisk. Wegovy Prescribing Information. Updated 2024.
10. Novo Nordisk. Ozempic Prescribing Information. Updated 2024.
11. FDA. Compounded Drugs: Questions and Answers for Patients. Updated October 2023.
12. American Medical Association. Recognition of Obesity as a Disease. Resolution 420 (A-13). 2013.
13. U.S. Department of Health and Human Services. Medicare Prescription Drug Benefit Manual, Chapter 6: Part D Drugs and Formulary Requirements. Updated 2024.
14. Kosiborod MN et al. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. New England Journal of Medicine. 2023.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy and Ozempic are registered trademarks of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk.